Boston Scientific Corp (BSX) 12.89 $BSX
How Will Boston Scientific (BSX) Stock Respond To This Coverage Initiation?
at The Street - Tue Jul 29, 8:29AM CDT
Boston Scientific (BSX) had coverage initiated with a 'neutral' at Sterne, Agee & Leach today.
Meridian Bioscience Q3 Earnings, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 12:58PM CDT
For fiscal 2014, Meridian Bioscience, Inc. (VIVO) expects earnings per share between 85 and 90 cents while revenues are expected in the range of $190 to $195 million.
Boston Scientific (BSX) Breaks Through Support at $12.98
Comtex SmarTrend(R) - Mon Jul 28, 12:27PM CDT
Shares of Boston Scientific (NYSE:BSX) have bearishly opened below the pivot of $13.14 today and have reached the first support level of $12.98. Analysts will be watching for a cross of the next downside pivot targets of $12.86 and $12.58.
AtriCure (ATRC) Jumps: Stock Adds 6.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 8:39AM CDT
AtriCure, Inc. (ATRC) was a big mover last session, as its shares rose nearly 7% on the day.
Abaxis (ABAX) Soars: Stock Rises 9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 7:51AM CDT
Abaxis, Inc. (ABAX) was a big mover last session, as its shares rose roughly 9% on the day.
Coronary Stents Market - Global Forecast to 2019
M2 - Mon Jul 28, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bczzxn/coronary_stents) has announced the addition of the "Coronary Stents Market - Global Industry Analysis, Size, Share, Pipeline Overview, Growth, Trends and Forecast, 2013 - 2019" report to their offering. A coronary stent is a tubular structured device made of a thin mesh of wire, which may also be coated with a polymer containing a drug, or made of biodegradable materials. Coronary stents are utilized during percutaneous coronary interventions (PCIs) for the treatment of patients suffering from various coronary artery diseases (CADs) such as acute myocardial infarction, angina pectoris and others. At present, several researches are being conducted in the field of coronary stenting, in order to minimize side effects such as restenosis and thrombosis. Certain new and advanced coronary stents such as bio-absorbable stents have been commercialized in the global market, which demonstrate very less or no common side effects of coronary stenting. The market for coronary stents can be broadly classified into three major segments, namely, bare metal stents (BMS), drug eluting stents (DES) and bio-absorbable stents. In 2011, the drug eluting stents segment held the largest share of the global coronary stents market, followed by the bare metal stents market. During the forecast period 2013 to 2019, the demand for bare metal stents is expected to be low and its overall growth will be offset by the increasing demand for other stent variants, mainly bio-absorbable stents. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Coronary Stents Market Overview Chapter 4 Global Coronary Stents Market, by Product Type Chapter 5 Global Coronary Stents Market: Pipeline Overview Chapter 6 Global Coronary Stents Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles Companies Mentioned: - Abbott Laboratories, Inc. - amg International GmbH - B. Braun Melsungen AG - Biotronik SE & Co. KG - Boston Scientific Corporation - C. R. Bard, Inc. - Cook Medical, Inc. - Johnson & Johnson - Medtronic, Inc. - MicroPort Scientific Corporation - STENTYS SA - Terumo Corporation For more information visit http://www.researchandmarkets.com/research/bc...ary_stents
Boston Scientific Stock Down Slightly on Earnings
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri Jul 25, 2:06PM CDT
All told, Boston Scientific did alright in the second quarter, but the inter-segment noise highlights one of the ongoing challenges for the company – keeping all the ducks in a row and delivering both top-line growth and margin...
AngioDynamics Q4 Earnings Beat, Revenues Up on Higher Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 2:25PM CDT
AngioDynamics Inc. (ANGO) introduced earnings and revenue guidance for the first quarter of fiscal 2015 as well as the entire fiscal year.
Boston Scientific Tops Q2 Earnings, Revenues; Ups EPS View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 11:15AM CDT
Boston Scientific (BSX) reported adjusted EPS of 14 cents in the second quarter of 2014.
Japan Cardiac Rhythm Management Market Report 2014-2019
M2 - Thu Jul 24, 10:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p57xfp/japan_cardiac) has announced the addition of the "Japan Cardiac Rhythm Management Market Report" report to their offering. This research report provides key market trends, market forecasts and competitive scenario of the cardiac rhythm management (CRM) in Japan through 2019. The product categories covered in this report include: - Pacemaker - Implantable Cardioverter Defibrillator (ICD) - Pacing & ICD leads - Electrophysiology lab systems Scope - Highlights and compares key product categories for growth trends and revenue forecast. - Market size, annualized revenue and unit sales for each product category from 2006 to 2019. - Cross category comparison - Growth and revenue comparison for product categories, historic and forecast through 2019. - Market share of companies. - Average selling price ($) for each product type (2006 to 2019). - Recent Events and Developments Key Topics Covered: 1. Tables & Charts 2. Introduction 3. Scope of the Report 4. Japanese Market for Cardiac Rhythm Management, 2006-2019 5. Recent Events and Developments 6. Appendix Companies Mentioned - Boston Scientific Corporation - Medtronic, Inc. - Sorin Group - St. Jude Medical Inc. For more information visit http://www.researchandmarkets.com/research/p5...an_cardiac
Boston Scientific Announces Results For Second Quarter Ended June 30, 2014
PR Newswire - Thu Jul 24, 6:00AM CDT
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.873 billion during the second quarter ended June 30, 2014, compared to the company's guidance range for the quarter of $1.840 to $1.890 billion. This represents 4 percent operational revenue growth (constant currency basis, excluding divested businesses) and 4 percent revenue growth on a reported basis, all compared to the prior year period. The company achieved adjusted earnings per share of $0.21 for the period, compared to $0.18 a year ago, and GAAP earnings of $4 million, or approximately $0.00 per share, compared to $0.10 a year ago.
After Yesterday's Rally of 1.32% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jul 23, 4:57PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $12.84 to a high of $13.04. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $12.97 on volume of 8.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SmarTrend Watching for Potential Pullback in Shares of Boston Scientific After 1.32% Gain
Comtex SmarTrend(R) - Wed Jul 23, 4:56PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $12.84 to a high of $13.04. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $12.97 on volume of 8.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Boston Scientific Receives CE Mark For Agent(TM) Drug-Coated Balloon
PR Newswire - Wed Jul 23, 4:00PM CDT
Continuing to advance the development of innovative treatment options for coronary artery disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European market launch of the Agent(TM) Paclitaxel-Coated PTCA Balloon Catheter. The Agent Drug-Coated Balloon (DCB) provides physicians with an additional alternative to treat both in-stent restenosis (ISR) and de novo small vessel coronary disease.
Boston Scientific Rises on Launch of POLARIS Imaging System - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 23, 3:55PM CDT
Share price of medical device major Boston Scientific Corporation (BSX) rose 2.4% yesterday, following the full commercial launch of its new POLARIS system
Boston Scientific (BSX) Crosses Pivot Point Resistance at $13.00
Comtex SmarTrend(R) - Wed Jul 23, 1:11PM CDT
Boston Scientific (NYSE:BSX) has opened bullishly above the pivot of $12.82 today and has reached the first level of resistance at $13.00. Investors may be interested in a cross of the next upside pivot targets of $13.14 and $13.46.
US Cardiac Catheters and Guidewires Market Trends and Forecasts, 2019
M2 - Wed Jul 23, 10:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h3q8kp/us_cardiac) has announced the addition of the "US Cardiac Catheters and Guidewires Market Trends and Forecast To 2019" report to their offering. This research report provides key market trends, market forecasts and competitive scenario of the cardiac catheters and guidewires in the US through 2019. The product categories covered in this report include: - Cardiac catheters - Guidewires Scope - Highlights and compares key product categories for growth trends and revenue forecast. - Market size, annualized revenue and unit sales for each product category from 2006 to 2019. - Cross category comparison - Growth and revenue comparison for product categories, historic and forecast through 2019. - Market share of companies. - Average selling price ($) for each product type (2006 to 2019). - Recent Events and Developments. Key Topics Covered: 1. Tables & Charts 2. Introduction 3. Scope of the Report 4. US Market for Cardiac Catheters and Guidewires, 2006-2019 5. Recent Events and Developments 6. Appendix Companies Mentioned - Abbott Laboratories - Biosense Webster (J&J) - Biotronik - Boston Scientific Corporation - Cordis Corporation - Maquet - Medtronic, Inc. - Sorin Group - St. Jude Medical Inc. - Terumo Medical Corporation For more information visit http://www.researchandmarkets.com/research/h3q8kp/us_cardiac
Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer
PR Newswire - Wed Jul 23, 7:00AM CDT
Silk Road Medical, Inc., a developer of advanced devices for the transcarotid treatment of intra- and extra-cranial cerebrovascular disease, announced today the appointment of Michael P. Wallace to the position of Chief Technology Officer. In this new role, Michael will lead the company's Research and Development efforts across its family of transcarotid access and treatment devices.
Why Boston Scientific (BSX) Stock Is Higher Today
at The Street - Tue Jul 22, 1:11PM CDT
Boston Scientific (BSX) is up after the medical solutions company launched the POLARIS Imaging System to better support IVUS catheters.
Former Stryker and Boston Scientific Manager Calvin Magee Named MDSave Executive Vice President and Board Member
Business Wire - Tue Jul 22, 11:11AM CDT
MDSave, the country's only consumer-driven health care technology company that allows patients to research, compare and purchase discounted health services directly from local physicians, announced today the appointment of Calvin Magee as executive vice president and board member.
How Will Boston Scientific (BSX) Stock Respond To This Coverage Initiation?
at The Street - Tue Jul 29, 8:29AM CDT
Boston Scientific (BSX) had coverage initiated with a 'neutral' at Sterne, Agee & Leach today.
Meridian Bioscience Q3 Earnings, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 12:58PM CDT
For fiscal 2014, Meridian Bioscience, Inc. (VIVO) expects earnings per share between 85 and 90 cents while revenues are expected in the range of $190 to $195 million.
Boston Scientific (BSX) Breaks Through Support at $12.98
Comtex SmarTrend(R) - Mon Jul 28, 12:27PM CDT
Shares of Boston Scientific (NYSE:BSX) have bearishly opened below the pivot of $13.14 today and have reached the first support level of $12.98. Analysts will be watching for a cross of the next downside pivot targets of $12.86 and $12.58.
AtriCure (ATRC) Jumps: Stock Adds 6.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 8:39AM CDT
AtriCure, Inc. (ATRC) was a big mover last session, as its shares rose nearly 7% on the day.
Abaxis (ABAX) Soars: Stock Rises 9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 7:51AM CDT
Abaxis, Inc. (ABAX) was a big mover last session, as its shares rose roughly 9% on the day.
Coronary Stents Market - Global Forecast to 2019
M2 - Mon Jul 28, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bczzxn/coronary_stents) has announced the addition of the "Coronary Stents Market - Global Industry Analysis, Size, Share, Pipeline Overview, Growth, Trends and Forecast, 2013 - 2019" report to their offering. A coronary stent is a tubular structured device made of a thin mesh of wire, which may also be coated with a polymer containing a drug, or made of biodegradable materials. Coronary stents are utilized during percutaneous coronary interventions (PCIs) for the treatment of patients suffering from various coronary artery diseases (CADs) such as acute myocardial infarction, angina pectoris and others. At present, several researches are being conducted in the field of coronary stenting, in order to minimize side effects such as restenosis and thrombosis. Certain new and advanced coronary stents such as bio-absorbable stents have been commercialized in the global market, which demonstrate very less or no common side effects of coronary stenting. The market for coronary stents can be broadly classified into three major segments, namely, bare metal stents (BMS), drug eluting stents (DES) and bio-absorbable stents. In 2011, the drug eluting stents segment held the largest share of the global coronary stents market, followed by the bare metal stents market. During the forecast period 2013 to 2019, the demand for bare metal stents is expected to be low and its overall growth will be offset by the increasing demand for other stent variants, mainly bio-absorbable stents. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Coronary Stents Market Overview Chapter 4 Global Coronary Stents Market, by Product Type Chapter 5 Global Coronary Stents Market: Pipeline Overview Chapter 6 Global Coronary Stents Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles Companies Mentioned: - Abbott Laboratories, Inc. - amg International GmbH - B. Braun Melsungen AG - Biotronik SE & Co. KG - Boston Scientific Corporation - C. R. Bard, Inc. - Cook Medical, Inc. - Johnson & Johnson - Medtronic, Inc. - MicroPort Scientific Corporation - STENTYS SA - Terumo Corporation For more information visit http://www.researchandmarkets.com/research/bc...ary_stents
Boston Scientific Stock Down Slightly on Earnings
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri Jul 25, 2:06PM CDT
All told, Boston Scientific did alright in the second quarter, but the inter-segment noise highlights one of the ongoing challenges for the company – keeping all the ducks in a row and delivering both top-line growth and margin...
AngioDynamics Q4 Earnings Beat, Revenues Up on Higher Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 2:25PM CDT
AngioDynamics Inc. (ANGO) introduced earnings and revenue guidance for the first quarter of fiscal 2015 as well as the entire fiscal year.
Boston Scientific Tops Q2 Earnings, Revenues; Ups EPS View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 11:15AM CDT
Boston Scientific (BSX) reported adjusted EPS of 14 cents in the second quarter of 2014.
Japan Cardiac Rhythm Management Market Report 2014-2019
M2 - Thu Jul 24, 10:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p57xfp/japan_cardiac) has announced the addition of the "Japan Cardiac Rhythm Management Market Report" report to their offering. This research report provides key market trends, market forecasts and competitive scenario of the cardiac rhythm management (CRM) in Japan through 2019. The product categories covered in this report include: - Pacemaker - Implantable Cardioverter Defibrillator (ICD) - Pacing & ICD leads - Electrophysiology lab systems Scope - Highlights and compares key product categories for growth trends and revenue forecast. - Market size, annualized revenue and unit sales for each product category from 2006 to 2019. - Cross category comparison - Growth and revenue comparison for product categories, historic and forecast through 2019. - Market share of companies. - Average selling price ($) for each product type (2006 to 2019). - Recent Events and Developments Key Topics Covered: 1. Tables & Charts 2. Introduction 3. Scope of the Report 4. Japanese Market for Cardiac Rhythm Management, 2006-2019 5. Recent Events and Developments 6. Appendix Companies Mentioned - Boston Scientific Corporation - Medtronic, Inc. - Sorin Group - St. Jude Medical Inc. For more information visit http://www.researchandmarkets.com/research/p5...an_cardiac
Boston Scientific Announces Results For Second Quarter Ended June 30, 2014
PR Newswire - Thu Jul 24, 6:00AM CDT
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.873 billion during the second quarter ended June 30, 2014, compared to the company's guidance range for the quarter of $1.840 to $1.890 billion. This represents 4 percent operational revenue growth (constant currency basis, excluding divested businesses) and 4 percent revenue growth on a reported basis, all compared to the prior year period. The company achieved adjusted earnings per share of $0.21 for the period, compared to $0.18 a year ago, and GAAP earnings of $4 million, or approximately $0.00 per share, compared to $0.10 a year ago.
After Yesterday's Rally of 1.32% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jul 23, 4:57PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $12.84 to a high of $13.04. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $12.97 on volume of 8.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SmarTrend Watching for Potential Pullback in Shares of Boston Scientific After 1.32% Gain
Comtex SmarTrend(R) - Wed Jul 23, 4:56PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $12.84 to a high of $13.04. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $12.97 on volume of 8.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Boston Scientific Receives CE Mark For Agent(TM) Drug-Coated Balloon
PR Newswire - Wed Jul 23, 4:00PM CDT
Continuing to advance the development of innovative treatment options for coronary artery disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European market launch of the Agent(TM) Paclitaxel-Coated PTCA Balloon Catheter. The Agent Drug-Coated Balloon (DCB) provides physicians with an additional alternative to treat both in-stent restenosis (ISR) and de novo small vessel coronary disease.
Boston Scientific Rises on Launch of POLARIS Imaging System - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 23, 3:55PM CDT
Share price of medical device major Boston Scientific Corporation (BSX) rose 2.4% yesterday, following the full commercial launch of its new POLARIS system
Boston Scientific (BSX) Crosses Pivot Point Resistance at $13.00
Comtex SmarTrend(R) - Wed Jul 23, 1:11PM CDT
Boston Scientific (NYSE:BSX) has opened bullishly above the pivot of $12.82 today and has reached the first level of resistance at $13.00. Investors may be interested in a cross of the next upside pivot targets of $13.14 and $13.46.
US Cardiac Catheters and Guidewires Market Trends and Forecasts, 2019
M2 - Wed Jul 23, 10:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h3q8kp/us_cardiac) has announced the addition of the "US Cardiac Catheters and Guidewires Market Trends and Forecast To 2019" report to their offering. This research report provides key market trends, market forecasts and competitive scenario of the cardiac catheters and guidewires in the US through 2019. The product categories covered in this report include: - Cardiac catheters - Guidewires Scope - Highlights and compares key product categories for growth trends and revenue forecast. - Market size, annualized revenue and unit sales for each product category from 2006 to 2019. - Cross category comparison - Growth and revenue comparison for product categories, historic and forecast through 2019. - Market share of companies. - Average selling price ($) for each product type (2006 to 2019). - Recent Events and Developments. Key Topics Covered: 1. Tables & Charts 2. Introduction 3. Scope of the Report 4. US Market for Cardiac Catheters and Guidewires, 2006-2019 5. Recent Events and Developments 6. Appendix Companies Mentioned - Abbott Laboratories - Biosense Webster (J&J) - Biotronik - Boston Scientific Corporation - Cordis Corporation - Maquet - Medtronic, Inc. - Sorin Group - St. Jude Medical Inc. - Terumo Medical Corporation For more information visit http://www.researchandmarkets.com/research/h3q8kp/us_cardiac
Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer
PR Newswire - Wed Jul 23, 7:00AM CDT
Silk Road Medical, Inc., a developer of advanced devices for the transcarotid treatment of intra- and extra-cranial cerebrovascular disease, announced today the appointment of Michael P. Wallace to the position of Chief Technology Officer. In this new role, Michael will lead the company's Research and Development efforts across its family of transcarotid access and treatment devices.
Why Boston Scientific (BSX) Stock Is Higher Today
at The Street - Tue Jul 22, 1:11PM CDT
Boston Scientific (BSX) is up after the medical solutions company launched the POLARIS Imaging System to better support IVUS catheters.
Former Stryker and Boston Scientific Manager Calvin Magee Named MDSave Executive Vice President and Board Member
Business Wire - Tue Jul 22, 11:11AM CDT
MDSave, the country's only consumer-driven health care technology company that allows patients to research, compare and purchase discounted health services directly from local physicians, announced today the appointment of Calvin Magee as executive vice president and board member.
